Drug Profile
Research programme: anticancer therapeutics - Beijing Tri-Prime Genetic Engineering
Latest Information Update: 05 Sep 2007
Price :
$50
*
At a glance
- Originator Beijing Tri-Prime Genetic Engineering
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2004 Preclinical trials in Cancer in China (unspecified route)